Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease

Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Asian Institute of Gastroenterology, Hyderabad, India

Background/Aims: Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and later onset PIBD (LO-PIBD) in India. Methods: We performed retrospective analysis of a large, prospectively maintained IBD registry. PIBD was divided into VEOIBD (<6 years) and LO-PIBD (6–17 years). Demographic data, disease characteristics and treatment were compared between the PIBD groups and with other Asian/Western studies as well as the adult patients of the registry. Results: Of 3,752 IBD patients, 292 (7.8%) had PIBD (0–17 years) (175 Crohn’s disease [CD], 113 ulcerative colitis [UC], 4 IBD-undifferentiated; 22 VEOIBD [7.5%], and 270 LO-PIBD [92.5%]). VEOIBD patients had more severe disease compared to LO-PIBD in both UC (P = 0.003) and CD (P < 0.001). Familial IBD was more common in VEOIBD (13.6%) compared to LO-PIBD (9.2%). Ileal disease (L1) was an independent risk factor for diagnostic delay in pediatric CD. Diagnostic delay (>6 months) was significantly lower in VEOIBD (40.9%) than in LO-PIBD (78.8%) (P < 0.001). Compared to other Asian and Western studies, extensive UC (72.5%) and complicated CD (stricturing/penetrating: 42.7%) were relatively more common. Perianal CD was relatively less frequent (7.4%). PIBD had a significantly higher number of complicated and ileal CD and extensive UC compared to adult cohort of the registry. Conclusions: VEOIBD has more aggressive phenotype than LO-PIBD. Disease appears distinct from other Asian and Western studies and adult onset disease, with more complicated CD and extensive UC. (Intest Res 2021;19:398-407)

Key Words: Inflammatory bowel diseases; Crohn disease; Ulcerative colitis; Very early onset IBD; Later onset pediatric IBD

INTRODUCTION

Pediatric inflammatory bowel disease (PIBD; age <17 years) constitutes up to 10%–25% of all IBD patients. Of these, a small proportion are very early onset IBD (VEOIBD; <6 years). VEOIBD appears to be a distinct subset of pediatric IBD with unique epidemiological and phenotypic characteristics including a severe and aggressive course of disease, predominant colonic involvement and a higher incidence of familial IBD compared to PIBD other than VEOIBD (6–17 years). The incidence of PIBD is on the rise globally. A complex interplay of genetic and changing environmental factors has been implicated for the rising incidence although specific factors are yet to be completely understood.

Most of the epidemiological data however are from the West including North America, Canada, and Europe. A few recent studies from Asia also suggest a rising trend of PIBD. Interestingly the phenotype appears to be distinct from that of the West including a milder ulcerative colitis (UC) and a higher perianal...
involvement in Crohn’s disease (CD). India is a large country with a large population where IBD is a new but emerging disease. Though the incidence of IBD is lower than that of the West expectedly, the burden of disease is high. The diagnosis of IBD itself poses significant challenges in a country where infectious diseases predominate, and tuberculosis (TB) is endemic.\(^{11,12}\)

Data on PIBD behavior and outcomes from India is limited. There are no published reports or separate analysis of VEOIBD and its differences from later onset disease. Similarities to adult IBD and distinctive features have been described in small and questionnaire-based studies.\(^ {5,13-20}\)

The primary aim of this study was to evaluate the disease characteristics and treatment patterns in VEOIBD and compare that to later onset PIBD (LO-PIBD: 6–17 years). We also compared our data with other PIBD or VEOIBD studies from Asia and the West.

**METHODS**

1. **Study Population**

   The study was conducted at the Asian Institute of Gastroenterology (AIG) in Hyderabad, India, a gastroenterology tertiary center for IBD patients across India. The IBD center was established in 2004 with a well-established prospectively maintained registry.\(^ {21}\)

   The registry includes the detailed history and demographic profile since the first visit, symptoms, disease activity scores, medication, and family history collected by interview and chart review. Clinical characteristics, including family history and response to treatment, are updated at each follow-up visit.\(^ {12,22}\)

   Eligible subjects included all patients with confirmed IBD who were less than 17 years of age up to November 2019. All patients underwent at least one ileo-colonoscopy and gastroscopy before enrolment into the registry. Patients with a follow-up of less than 6 months were excluded from the study.

   The diagnosis of IBD was based on the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPN-ghan) “Porto” criteria including history, clinical, endoscopic, histologic and radiologic features.\(^ {23}\) Small bowel evaluation was done by magnetic resonance enterography in majority of the cases. Computed tomography enterography was used in very limited numbers due to risk of radiation. A chest X-ray, 2 step Mantoux and biopsy specimen polymerase chain reaction for Mycobacterium. TB DNA were done to rule out TB in CD patients. Clinical, endoscopic, radiologic features and histopathology were considered for differentiating intestinal TB from CD. Empirical anti-TB therapy (ATT) was initiated when diagnostic dilemma persisted even after extensive evaluation. An assessment for response is done at 2 months. In case of improvement, ATT is continued for at least 6 months.

   The patients were classified as VEOIBD < 6 years of age, and LO-PIBD for patients between 6 and 17 years of age. The subgroup of patients less than 2 years of age were identified as infantile onset IBD (IOIBD). Demographic data including age, sex, family history, clinical symptoms at presentation (abdominal pain, diarrhea, weight loss, and rectal bleeding) and presence of extraintestinal manifestations was retrieved from the registry. The diagnostic delay was calculated based on the difference between the age of onset of symptoms and the age at diagnosis.

2. **Disease Extension and Severity**

   The location of the disease was noted using the pediatric modification of Montreal classification (Paris classification) for the purpose of the study.\(^ {24}\) The disease activity at presentation was recorded according to the Pediatric Crohn’s Disease Activity Index (PCDAI) and the Pediatric Ulcerative Colitis Activity Index (PUCAI).\(^ {25,26}\) The maximum extent recorded and the maximum severity noted were included in the analysis.

   The treatment given including the requirement of steroids, immunomodulators and biologics was presence of complications and need for surgeries were recorded.

3. **Statistical Methods**

   The IBD registry runs on Apex healthcare management system software which allows entry of follow-up data at each visit. The data for the PIBD and VEOIBD patients were reviewed for completeness and consistency before entering into Microsoft Excel (Microsoft Corp., Redmond, WA, USA).

   Continuous variables were expressed as mean (95% confidence interval [CI]) if normally distributed or as median and interquartile range (IQR)/range if not normally distributed. Normality of distribution was ascertained by the Kolmogorov-Smirnov test and the Shapiro-Wilk test \(P < 0.05\) indicates non-normal distribution). Categorical variables were expressed as frequencies and percentages. Patient characteristics were compared using Student t-test (for data with normal distribution) and Mann-Whitney test (for non-parametric data/data with non-normal distribution with 2 groups) for continuous variables and chi-square/Fisher exact test (depending on sample size and expected values) for categorical variables. Univariate
followed by multivariate logistic regression analysis was performed to look for risk factors of diagnostic delay (>50th percentile) in CD and UC and also to assess risk factors for surgery in CD. P-values of < 0.05 were considered statistically significant. The data were analyzed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

4. Ethical Considerations
All patients seen at the clinic with a confirmed diagnosis of IBD are enrolled into the registry after informed consent including permission to use information for research purposes. For pediatric cases (age of onset < 17 years) informed consent is obtained from the parent or legal guardian. The study was approved by the Institutional Review Board of Asian Institute of Gastroenterology (AIG AHF IRB No. 07/2019) and performed in accordance with the principles of the Declaration of Helsinki.

RESULTS

1. Demographics and Disease Presentation
The AIG IBD registry included 3,752 patients. Of these, 292 subjects (7.8%) comprised the PIBD cohort (age < 17 years). Majority (n = 270, 92.5%) of the PIBD cases belonged to the LO-PIBD group (6–17 years). VEOIBD (< 6 years) and IOIBD (< 2 years) were identified in 22 (7.5%) and 8 (2.7%) children, respectively. The distribution of the pediatric cases according to age is shown in Fig. 1A.

There were more cases of CD (59.9%, 175/292) than UC (38.7%, 113/292) in all the age groups. IBD-undifferentiated (IBD-U) was seen in 4 patients (1.4%). CD was diagnosed in 13 (59.1%) and UC in 8 (36.3%) of VEOIBD cases. IBD-U was seen in 1 patient (4.5%) of VEOIBD group.

The presenting symptoms of VEOIBD are tabulated in Tables 1 and 2. There were no significant differences in the

---

Fig. 1. Age distribution, disease extent, and phenotype of PIBD. (A) Distribution of UC and CD cases according to age groups. (B) Extent of disease in UC: VEOIBD and LO-PIBD patients. (C) Extent of disease in CD: VEOIBD and LO-PIBD patients. (D) Disease behavior in CD: VEOIBD and LO-PIBD patients. IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IBD-U, undifferentiated IBD; VEOIBD, very early onset IBD; LO-PIBD, later onset pediatric IBD; E1, proctitis; E2, upto splenic flexure; E3, upto hepatic flexure; E4, pancolitis; L1, ileal; L2, colonic; L3, ileo-colonic; L4a, upper gastrointestinal disease upto ligament of Treitz; L4b, beyond ligament of Treitz upto distal ileum CD; B1, inflammatory; B2, stricturing disease; B3, fistulizing CD; p, perianal disease.
2. Family History
A family history of IBD was noted in 3 (13.6%) of VEOIBD and 25 (9.2%) children with LO-PIBD ($P=0.70$). Three (13.6%) of VEOIBD and 18 (6.6%) of LO-PIBD were born of consanguineous marriage ($P=0.38$).

3. Delay in Diagnosis
Diagnostic delay (> 6 months) was significantly lower in VEOIBD (40.9%) than in LO-PIBD (78.8%) ($P<0.001$). The median diagnostic delay in VEOIBD and LO-PIBD were 6 months (IQR, 2–30 months) and 12 months (IQR, 7–24 months), respectively ($P=0.034$). On further analysis, there was no significant difference in diagnostic delays between UC (median, 18 months; IQR, 3–29 months) and CD (median, 20 months; IQR, 6–30 months) in each group ($P=0.30$).

4. Risk Factors for Diagnostic Delay
Logistic regression analyses of risk factors for diagnostic delays (> 50th percentile) in the diagnosis of CD and UC are depicted in Table 3. In CD, ileal disease was a risk factor for diagnostic delay (> 50th percentile) ($P=0.03$; odds ratio [OR], 2.16). In UC, none of the factors were predictive except age > 10 years (which nearly achieved significance: $P=0.06$; OR, 0.21).

5. ATT Prior to Diagnosis
A total of 31 children (17.7%; 2 in VEOIBD, 29 in LO-PIBD) of pediatric CD received ATT prior to diagnosis. Pediatric UC patients of 1.8% (2/113) received ATT. Empirical ATT use was lower in VEOIBD compared to LO-PIBD, but not statistically significant ($P=0.49$).

6. Disease Extent and Severity
Fig. 1B and C show the extent of disease in UC and CD in VEOIBD and LO-PIBD patients.

1) Ulcerative Colitis
A higher proportion of patients with VEOIBD had extensive colitis compared to LO-PIBD (62.5% vs. 50.5%). However, the difference was not statistically significant ($P=0.68$) (Fig. 1B). Similarly, the severity of disease was significantly higher for VEOIBD than LO-PIBD (Table 2). The median PUCAI score for VEOIBD was 60 (range, 45–80). The severity of disease according to the PUCAI score was moderate and severe in 37.5% and 62.5%, respectively with no mild cases. This was significantly higher than in LO-PIBD where 35% had mild disease (Table 2).
### Table 2. Disease Characteristics of VEOIBD (< 6 Years) and LO-PIBD (6–17 Years) Separately in Ulcerative Colitis and Crohn’s Disease

| Characteristics | UC, No. (%) | CD, No. (%) | P-value | UC, No. (%) | CD, No. (%) | P-value |
|-----------------|-------------|-------------|---------|-------------|-------------|---------|
| **Age of onset (yr)** |             |             | 0.170   |             |             | <0.001  |
| Mean ±SD        | 2.50 ± 1.41 | 13.66 ± 4.08| 3.55 ± 1.44 | 13.51 ± 3.10 |             |         |
| Median (IQR)    | 2.5 (1–4)   | 15 (13–17)  | 4 (2–5)   | 14 (11.7–16) |             |         |
| **Diagnostic delay (mo)** |             |             | 0.140   |             |             | 0.530   |
| Mean (range)    | 6.2 (1–12)  | 20.6 (1–120)| 19.0 (1–60) | 24.0 (1–120) |             |         |
| SD              | 3.3         | 27.4        | 20.4     | 28.3        |             |         |
| Median (IQR)    | 6 (3–9)     | 11 (6–24)   | 19 (3.25–36) | 12 (7–24)   |             |         |

**Clinical features**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| Abdominal pain      | 5 (62.5)     | 59 (56.2)       | 0.510   | 6 (46.2)     | 121 (74.7)      | 0.470   |
| Diarrhea            | 7 (87.5)     | 82 (78.1)       | 0.680   | 10 (76.9)    | 102 (62.9)      | 0.550   |
| Blood in stool      | 7 (87.5)     | 88 (83.8)       | 0.630   | 7 (53.8)     | 51 (31.5)       | 0.130   |
| Mucus in stool      | 6 (75.0)     | 53 (50.5)       | 0.270   | 4 (30.8)     | 35 (21.6)       | 0.490   |
| Weight loss         | 3 (37.5)     | 49 (46.7)       | 0.720   | 5 (38.5)     | 86 (53.1)       | 0.390   |
| Fever               | 3 (37.5)     | 22 (20.9)       | 0.370   | 5 (38.5)     | 55 (33.9)       | 0.770   |
| EIMs                | 2 (25.0)     | 27 (25.7)       | 0.660   | 3 (23.1)     | 32 (19.8)       | 0.500   |
| Family history of IBD | 1 (12.5) | 10 (9.5)       | 0.570   | 2 (15.4)     | 15 (9.2)        | 0.600   |
| History of consanguinity | 2 (25.0) | 6 (5.7)        | 0.090   | 1 (7.7)      | 12 (7.4)        | 0.640   |

**Extent of disease (UC)**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| Proctitis (E1)      | 2 (25.0)     | 12 (11.4)       |        |              |                 |         |
| Procto-sigmoiditis (E2) | 1 (12.5) | 16 (15.2)       |        |              |                 |         |
| Upto hepatic flexure (E3) | 0        | 24 (22.9)       |        |              |                 |         |
| Pancolitis          | 5 (62.5)     | 53 (50.5)       |        |              |                 |         |

**Extent of disease (CD)**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| L1 (ileal)          | 2 (15.4)     | 53 (32.9)       |        |              |                 |         |
| L2 (colonics)       | 2 (20.9)     | 61 (37.7)       |        |              |                 |         |
| L3 (ileo-colonics)  | 6 (46.1)     | 40 (24.7)       |        |              |                 |         |
| L4a+L4b\(^a\)      | 1 (7.7)      | 8 (5.0)         |        |              |                 |         |

**Disease behavior (CD)**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| Inflammatory (B1)   | 9 (69.2)     | 91 (56.2)       |        |              |                 |         |
| Strictureing (B2)   | 3 (23.1)     | 54 (33.3)       |        |              |                 |         |
| Fistulizing (B3)    | 1 (7.7)      | 17 (10.5)       |        |              |                 |         |
| Perianal (p)        | 1 (7.7)      | 12 (7.4)        |        |              |                 | 0.968   |

**Disease severity\(^b\)**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| Mild disease        | 0            | 37 (35.2)       |        | 1 (7.7)      | 53 (32.7)       |        |
| Moderate disease    | 3 (37.5)     | 55 (52.4)       |        | 2 (15.4)     | 97 (59.9)       |        |
| Severe disease      | 5 (62.5)     | 13 (12.3)       |        | 10 (76.9)    | 25 (15.4)       |        |

**Treatment history**

|                     | VEOIBD (n=8) | LO-PIBD (n=105) | P-value | VEOIBD (n=13) | LO-PIBD (n=162) | P-value |
|---------------------|--------------|-----------------|---------|--------------|-----------------|---------|
| 5-ASA               | 8 (100.0)    | 105 (100.0)     | 1.000   | 11 (84.6)    | 151 (93.2)      | 0.250   |
| Steroids            | 6 (75.0)     | 58 (55.2)       | 0.460   | 10 (76.9)    | 112 (69.1)      | 0.600   |
| Immunomodulators    | 4 (50.0)     | 44 (41.9)       | 0.720   | 8 (61.5)     | 96 (59.2)       | 0.760   |
| Biologics           | 1 (12.5)     | 6 (5.7)         | 0.410   | 1 (7.7)      | 9 (5.5)         | 0.510   |
| Surgery             | 1 (12.5)     | 2 (1.9)         | 0.190   | 1 (7.7)      | 28 (17.2)       | 0.480   |
| ATT                 | 0            | 2 (1.9)         | 1.000   | 2 (15.4)     | 27 (16.6)       | 0.630   |

\(^a\)VEOIBD is 0+1 and LO-PIBD is 3+5.

\(^b\)UC was classified as Pediatric Ulcerative Colitis Activity Index and CD as Pediatric Crohn’s Disease Activity Index.

IBD, inflammatory bowel disease; VEOIBD, very early onset IBD; LO-PIBD, later onset pediatric IBD; UC, ulcerative colitis; CD, Crohn’s disease; SD, standard deviation; IQR, interquartile range; EIM, extraintestinal manifestation; ASA, aminosalicylic acid; ATT, anti-tubercular therapy.
with UC was lost to follow-up for more than 2 years and expired at 5 years of age presumably due to septicemia. The 5 other cases with IOIBD also had a severe disease course with multiple relapses needing steroids.

8. Treatment Received
There was no significant difference in the use of biologics, steroids, 5-aminosalicylic acid (5-ASA), and immune modulators (azathioprine/methotrexate) between VEOIBD and LO-PIBD (in total as well as in subgroups of UC and CD there was no significant difference) (Table 2).

All patients with UC received 5-ASA. Sixty-four out of 113 patients (56.6%) required a course of steroids. Steroid dependent and refractory UC were put on immunomodulators to maintain remission (42.4%, 48/113). Eleven out of 113 patients with UC (9.7%) had frequent relapsing course of disease (>3 relapses a year) and 3 patients had acute severe colitis requiring surgery (2.65%). Fifteen out of 175 CD patients (8.5%) had >3 relapses in a year. Steroid and azathioprine requirements were higher in CD but biologic usage was still low (5.7%, 10/175) (Table 2). Thirty-seven out of 175 CD patients (21.1%) received partial enteral nutrition (PEN) (approximately half of the daily calorie requirement) in addition to other therapy.

Surgery was required in 3 of 22 (13.6%) of VEOIBD and 29 of 270 (10.7%) LO-PIBD children. These included proctocolectomy (1), sub-total colectomy (3), right hemicolectomy (1), segmental small bowel resection (12 ileal, 6 jejunal) and ileocecal resection (5). Fistulectomy and examination under anesthesia with seton placement was done in 4 patients. 16.5% (29/175) patients with CD and 2.4% (3/114) patients with UC underwent surgery. Logistic regression analysis was done to assess for risk factors of surgery—none of the risk factors significantly predicted surgery (Supplementary Table 1). There were 4 teenage smokers in our pediatric cohort (3 CD and 1 UC).

DISCUSSION

This is a retrospective analysis of prospectively maintained database of a large number of PIBD patients. This is the first study from India that has highlighted the disease characteristics and treatment patterns of PIBD particularly VEOIBD and IOIBD and compared the differences with later onset disease (6–17 years). Severity of disease was significantly higher in VEOIBD (in both UC and CD subgroups) compared to later onset disease (P = 0.003 and P = 0.001, respectively) consistent with earlier studies.37,28
A family history of IBD was found in 14% patients with VEOIBD compared to 9% in later onset disease. The entire cohort from our registry has a positive family history in only 4% (CD of 4.13% and UC of 4.34%) which we have published recently. This has been reported in many other studies that familial IBD is less common in Asia than the West. This clearly demonstrates that a genetic predisposition to IBD correlates with the onset of disease being highest in the IOIBD and VEOIBD.

We compared our data with that of other studies both in Asia and the West (Supplementary Tables 2, 3). The large Western population-based Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD) (1,412 PIBD patients) was used for comparison (Supplementary Table 2). Male preponderance was more evident (82% vs. 52%, P = 0.0002). The VEOIBD disease character otherwise was similar to our study. Interestingly the LO-PIBD group in our study had significant differences compared to EPIMAD study. A higher number of patients had a diagnostic delay > 6 months (78.8% vs. 30%, P = 0.0004) and the incidence of familial IBD (9.2% vs. 15%, P= 0.0099) was significantly lower. The Indian PIBD appears to be more severe with a higher incidence of structuring and penetrating disease (B2 and B3) in CD and pan colitis (E4) in UC compared to EPIMAD cohort.

We also compared our data with other PIBD cohorts from Asia and Europe (Supplementary Table 3). We noted a high incidence of ileal CD (31.4%) though colonic disease was most common (37.1%). Another Indian study by Sonavane et al. similarly showed that the most common phenotype was ileal (37.5%). Perianal disease and upper gastrointestinal (L4) was less common. A recent study on PIBD from East Asia (Japan) showed higher incidence of upper gastrointestinal and perianal disease compared to European Cohort (EUROKIDS). The incidence of structuring and fistulizing disease was significantly higher than other studies. The rates of surgery in CD (16.5%) comparable to other Asian study (South Korea, 22.7%). In UC, although pan colitis was the most common phenotype, colectomy rates were lower (2.7%) supporting the notion that UC is a milder disease in Asian countries with less incidence of acute severe colitis and colectomy (Supplementary Table 3). Compared to another questionnaire-based survey from India by Sathiyasekaran et al., the proportion of VEOIBD, disease location and proportion of perianal CD were different. Such differences could be due to variation in methods of data collection and study settings. However, results appear more consistent with a recent study from India by Sonavane et al.

We found that a diagnostic delay > 6 months was lesser in VEOIBD compared to later onset disease (40.9% vs. 78.8%, P = 0.0001) disease perhaps because of more severe disease at presentation prompting early referral in VEOIBD. Another plausible explanation could be the use of diapers in infants and hence easier observation of their stools. Ileal disease (L1) was predictive of longer diagnostic delay (> 50th percentile) in CD. This is in sharp contrast to the EPIMAD study where diagnostic delay > 6 months were seen in only 27% and 30% patients respectively in VEOIBD and LO-PIBD. The disproportionately longer delay in diagnosis could be attributable to poor physician awareness of pediatric IBD in India and high percentage of ileal (31.4%) disease in our study which is a known risk factor for diagnostic delay in pediatric CD.

The other contributory factors for diagnostic delay include the infectious mimics of IBD and over the counter antibiotics (like fluoroquinolone and metronidazole) are easily available and is often the first line of treatment. The high prevalence of TB which is often symptomatically, endoscopically and histopathologically difficult to differentiate from ileo-colonic CD is another diagnostic dilemma which results in empirical use of ATT. Almost one-fifth of children with CD in our cohort had received ATT prior to diagnosis adding to diagnostic delay. We have earlier reported that empirical use of ATT was the single largest contributor for diagnostic delay in an adult CD cohort of more than 700 patients which resulted in higher long term stenotic complications and need for surgery. India is endemic for TB and there is limited awareness about CD. Hence at the community level, patients are initiated on ATT and CD is diagnosed only if there is no response leading toordinate delays in diagnosis.

We also compared data between the adult and PIBD cohort in our registry (Supplementary Table 4). Familial IBD was more common in PIBD cohort. Higher incidence of ileal disease (L1), strictureing phenotype (B2) and perianal disease was found in pediatric CD cohort. UC in PIBD cohort was more extensive. Steroid, immunomodulator, and biologic usage was also higher in PIBD group. However, the diagnostic delay was significantly higher (P < 0.0001) in adults with CD (mean ± standard deviation [SD], 42.2 ± 46.1 months) compared to pediatric CD (mean ± SD, 23.56 ± 27.76 months). This could be attributable to the higher usage of empirical ATT in the adult cohort.

IOIBD was seen in 8 children (2.7% of PIBD). Three had refractory disease requiring surgery. IL-10 receptor mutation was detected in 1 child who later underwent allogenic hematopoietic stem cell transplantation. This is very much in con-
cordance with other studies from across the globe suggesting that IOIBD is a distinct and the most difficult to treat subset of pediatric IBD. Monogenic defects like IL-10/IL-10R mutations are not uncommon in this subgroup. However, muta-
tional defects often go undetected due to unavailability of re-
quired facilities and financial constraints in emerging econo-
 mies like India. Only 1 of our VEOIBD patients was tested for receptor mutations.

The rate of steroid and biologic usage did not differ between the VEOIBD and LO-PIBD group. Although the disease severity was high and complicated and extensive disease phenotypes were common in our study, biologic usage was limited in our study. The risk of opportunistic infections, high prevalence of latent TB and of course the high cost with limited or no insurance coverage precludes biological therapy in the re-
source limited country settings like India. Exclusive enteral nutrition was not used due to poor acceptability and compli-
ance in addition to cost concerns. However, PEN was used as an adjunct to other therapies. PEN in CD is known to be asso-
ciated with an extended period of disease remission.

We acknowledge certain limitations including, the relatively small number of children in VEOIBD group and inability to perform mutation analysis in a large fraction of children. We did not assess all the PIBD patients routinely for growth fail-
ure- so we could not assess the extent of growth failure in vari-
ous groups which is important aspect of PIBD specialty in CD. It was also a single tertiary care center analysis with the possi-
bility of overrepresentation of severe disease. Comparisons with the Western and other Asian data are at best tentative.

This is the first PIBD cohort from India highlighting the dif-
fences between VEOIBD and LO-PIBD in children. VEOIBD though uncommon was associated with more severe disease and poorer outcomes compared to later onset disease. VEOI-
BD in India was phenotypically similar to the West although later onset (6–17 years) disease phenotype differed. Large multicenter studies based on prospective databases are re-
quired to confirm whether PIBD in India is phenotypically dif-
f erent. We found that diagnostic delays were common and most children received multiple courses of antibiotics before confirmation of diagnosis. This would have significant long term prognostic implications. This study highlights the urgent need for increasing the awareness on the prevalence of IBD in the pediatric population amongst primary care physicians to ensure early diagnosis and timely treatment of this chronic disease.

ADDITIONAL INFORMATION

Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Author Contribution
Conceptualization: Banerjee R. Data curation: Pal P, Shava U, Ganesh G. Formal analysis: Pal P. Investigation: Pal P. Method-
ology: Banerjee R. Project administration: Banerjee R, Reddy DN. Resources: Banerjee R. Supervision: Banerjee R. Visual-
ization: Banerjee R, Pal P. Writing - original draft: Banerjee R, Pal P, Nabi Z, Shava U, Ganesh G. Writing - review & editing: all authors. Approval of final manuscript: all authors.

ORCID
Banerjee R https://orcid.org/0000-0002-3753-4933
Pal P https://orcid.org/0000-0002-7090-9004
Nabi Z https://orcid.org/0000-0003-2713-4781
Shava U https://orcid.org/0000-0002-2233-0161
Ganesh G https://orcid.org/0000-0002-3909-4206
Reddy DN https://orcid.org/0000-0001-7540-0496

Supplementary Material
Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

REFERENCES

1. Conrad MA, Rosh JR. Pediatric inflammatory bowel disease. Pediatr Clin North Am 2017;64:577-591.
2. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric in-
flammatory bowel disease: a systematic review of interna-
tional trends. Inflamm Bowel Dis 2011;17:423-439.
3. Roberts SE, Thorne K, Thapar N, et al. A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohns Colitis 2020; 14:1119-1148.
4. Huang JG, Aw MM. Pediatric inflammatory bowel disease in Asia: epidemiology and natural history. Pediatr Neonatal 2020; 61:263-271.
5. Ong C, Aw MM, Liwanag MJ, Quak SH, Phua KB. Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015. J Dig Dis 2018;19:395-403.
6. Shen YM, Wu JF, Chen HL, et al. Characteristics and incidences of pediatric Crohn's disease in the decades before and after 2000. Pediatr Neonatol 2011;52:317-320.
7. Dalzell AM, Ba' Ath ME. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries. Paediatr Int Child Health 2019;39:48-58.
8. Wang XQ, Zhang Y, Xu CD, et al. Inflammatory bowel disease in Chinese children: a multicenter analysis over a decade from Shanghai. Inflamm Bowel Dis 2013;19:423-428.
9. Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and clinical outcomes of inflammatory bowel disease in South Korea. 2011-2014: a nationwide population-based study. Dig Dis Sci 2017;62:2102-2112.
10. Banerjee R, Basavaraju U, Adigopula B, Reddy N. A well-maintained inflammatory bowel disease (IBD) registry can help assess and optimise treatment for the local population: a 10-year experience in an Indian IBD registry cohort. J Crohns Colitis 2016;10(Suppl 1):S469–S470.
11. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.
12. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-1321.
13. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-447.
14. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-432.
15. Kelsen JR, Conrad MA, Dawany N, et al. The unique disease course of children with very early onset-inflammatory bowel disease. Inflamm Bowel Dis 2020;26:909-918.
16. Moon JS. Clinical aspects and treatments for pediatric inflammatory bowel disease. Intest Res 2019;17:17-23.
17. Bayless TM, Tokayer AZ, Polito JM 2nd, Quaskey SA, Mellits ED, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members—potential hereditary influences. Gastroenterology 1996;111:573-579.
18. Bequet E, Sarter H, Fumery M, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohns Colitis 2016;10(Suppl 1):S469–S470.
32. de Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 2013;19:378-385.
33. Arai K, Kunisaki R, Kakuta F, et al. Phenotypic characteristics of pediatric inflammatory bowel disease in Japan: results from a multicenter registry. Intest Res 2020;18:412-420.
34. Kim HJ, Oh SH, Kim DY, et al. Clinical characteristics and long-term outcomes of paediatric Crohn's disease: a single-centre experience. J Crohns Colitis 2017;11:157-164.
35. Hong SJ, Cho SM, Choe BH, et al. Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook province in Korea: a multi-center study. J Korean Med Sci 2018;33:e132.
36. Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (NY) 2016;12:193-196.
37. Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology 2016;150:86-95.
38. El Mouzan MI, AlSaleem BI, Hasosah MY, et al. Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia. Saudi J Gastroenterol 2019;25:257-261.
39. Leong RW, Mitrev N, Ko Y. Hygiene hypothesis: is the evidence the same all over the world? Dig Dis 2016;34:35-42.
40. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010;105:2687-2692.
41. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011;60:49-54.
42. Ma JY, Tong JL, Ran ZH. Intestinal tuberculosis and Crohn's disease: challenging differential diagnosis. J Dig Dis 2016;17:155-161.
43. Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther 2018;47:1367-1374.
44. Kammermeier J, Dziubak R, Pescarin M, et al. Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years. J Crohns Colitis 2017;11:60-69.
45. Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007.
46. Zhu L, Shi T, Zhong C, Wang Y, Chang M, Liu X. IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease. Gastroenterology Res 2017;10:65-69.
47. Ng SC, Chan FK. Infections and inflammatory bowel disease: challenges in Asia. J Dig Dis 2013;14:567-573.
48. Di Caro S, Fragkos KC, Keetarut K, et al. Enteral nutrition in adult Crohn's Disease: toward a paradigm shift. Nutrients 2019;11:2222.
49. Ishige T. Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 2019;8:16-22.
See “Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease” on page 398-407.

### Supplementary Table 1. Logistic Regression Analysis of Risk Factors of Surgery

| Risk factor                                | P-value | OR   | 95% CI          |
|--------------------------------------------|---------|------|-----------------|
| Location of disease (ileal or colonic)     | 0.78    | 0.88 | 0.36–2.16       |
| Disease behavior (B2 or others)            | 0.56    | 1.32 | 0.52–3.35       |
| Smoking (yes or no)                        | 0.99    | 4.02 | 0.01–8.42       |
| ATT (yes or no)                            | 0.05    | 0.38 | 0.14–1.00       |
| Sex (male or female)                       | 0.79    | 1.12 | 0.48–2.63       |
| Onset of symptoms (≤ 10 or > 10 yr)        | 0.34    | 0.56 | 0.17–1.82       |
| Diagnostic delay (> 1 or < 1 yr)           | 0.37    | 1.47 | 0.63–3.43       |
| Family history (yes or no)                 | 0.22    | 3.79 | 0.46–31.58      |

OR, odds ratio; CI, confidence interval; ATT, anti-tubercular therapy.
### Supplementary Table 2. Comparison of Pediatric Inflammatory Bowel Disease Data with French Population-Based Registry (EPIMAD)

| Variable                           | VEOIBD, % (No./No.) | LO-PIBD, % (No./No.) | P-value |
|------------------------------------|---------------------|----------------------|---------|
|                                   | India               | EPIMAD               |         |
| No. of patients (%)                | 22 (7.5)            | 42 (3)               | 0.003   |
| CD:UC:IBD-U (%)                    | 59.1:36.4:4.5       | 60:33.7              | 0.90    |
| Male sex                           | 82 (18/22)          | 52 (22/42)           | 0.02    |
| Diagnostic delay > 6 mo            | 40.9 (9/22)         | 27 (11/42)           | 0.23    |
| Family history of IBD              | 13.6 (3/22)         | 9.5 (4/42)           | 1       |
| Diarrhea                           | 77.2 (17/22)        | 76 (32/42)           | 0.92    |
| Blood in stool                     | 68.2 (15/22)        | 81 (34/42)           | 0.25    |
| Mucus in stool                     | 50 (11/22)          | 40 (17/42)           | 0.47    |
| Weight loss                        | 36.4 (8/22)         | 21 (9/42)            | 0.19    |
| Abdominal pain                     | 50 (11/22)          | 43 (18/42)           | 0.58    |
| EIM                                | 22.7 (5/22)         | 17 (7/42)            | 0.74    |
| Perianal disease                   | 7.69 (1/13)         | 8 (2/25)             |         |
| Crohn's disease                    |                     |                      |         |
| Bleeding per rectum                | 53.8 (7/13)         | 68 (17/25)           | 0.48    |
| Abdominal pain                     | 46.2 (6/13)         | 48 (12/25)           | 0.92    |
| Weight loss                        | 38.5 (5/13)         | 20 (5/25)            | 0.26    |
| EIM                                | 23.1 (3/13)         | 20 (5/25)            | 0.57    |
| Colonic disease L2                 | 30.8 (4/13)         | 39 (9/25)            | 0.52    |
| B2+B3 disease in CD                | 30.8 (4/13)         | 13 (3/25)            | 0.20    |
| Ulcerative colitis                 |                     |                      |         |
| Abdominal pain                     | 62.5 (5/8)          | 21 (3/14)            | 0.08    |
| EIM                                | 25 (2/8)            | 7 (1/14)             | 0.53    |
| Proctitis (E1)                     | 25 (2/8)            | 9 (1/11)             | 0.32    |
| Procto-sigmoiditis (E2)            | 12.5 (1/8)          | 36 (4/11)            | 15.2    |
| Upto hepatic flexure(E3)           | 0 (0/8)             | 27 (3/11)            | 22.9    |
| Pancolitis (E4)                    | 62.5 (5/8)          | 27 (3/11)            | 0.50    |

EPIMAD, epidemiology of inflammatory bowel diseases; new insights from a French population-based registry; IBD, inflammatory bowel disease; VEOIBD, very early onset IBD; LO-PIBD, later onset pediatric IBD; CD, Crohn’s disease; UC, ulcerative colitis; IBD-U, IBD undifferentiated; EIM, extraintestinal manifestations; L2, colonic CD; B2, stricturing disease; B3, fistulizing CD.
## Supplementary Table 3. PIBD Data Comparison with Indian, Asian and Western Studies

| Variable | Sathiasekaran et al.\(^{16}\) (n = 221) | Sonawane et al.\(^{17}\) (n = 65) | AIG PIBD cohort (n = 292) | South Korea\(^{34,35}\) (n = 574) | EUROKIDS\(^{33}\) (n = 3,461) |
|----------|----------------------------------------|---------------------------------|--------------------------|-------------------------------|-------------------------------|
| Disease phenotype, CD/UC/IBD-U | 55.2/42.1/2.7 | 63/37/0 | 60/39/1 | 80.3/19.7/0 | 60.2/32.1/7.7 |
| CD:UC | 1.38:1 | 1.7:1 | 1.55:1 | 4.08:1 | 1.87:1 |
| Male sex, UC/CD | 54.8/47.5 | 75.0/75.0 | 63.7/62.0 | 45.8/60.6 | 50.9/60.1 |
| Mean age at diagnosis, UC/CD | 10.2/11 | NA/NA | 13.6/12.7 | 12.9/13.7 | 12.9/13.3 |
| VEOIBD | 15.8 | NA | 7.5 | NA | NA |
| CD | | | | | |
| VEOIBD (< 6 yr) | 15.8 | NA | 7.5 | NA | NA |
| Age < 10 yr (A1a) | 32.8 | NA | 17.1 | 2.4 | 20.0 |
| Age 10-17 yr (A1b) | 45.9 | NA | 82.9 | 73.7 | 80.0 |
| Disease location in CD | | | | | |
| L1 (ileal) | 8.2 | 37.5 | 31.4 | 10.7 | 16.0 |
| L2 (colonic) | 12.3 | 29.1 | 37.1 | 8.2 | 27.0 |
| L3 (ileocolonic) | 72.9 | 33.3 | 26.2 | 79.3 | 53.0 |
| L4 (upper GI) | 11.5 | 0 | 5.1 | 25.8 | 49.5 |
| B1 (inflammatory) | 73.0 | 79.1 | 57.1 | 88.9 | 82.0 |
| B2 (stricturing) | 6.5 | 8.3 | 32.5 | 9.4 | 12.0 |
| B3 (fistulizing) | - | 12.5 | 10.2 | 1.6 | 5.0 |
| Perianal disease | 18.0 | NA | 7.4 | 47.1 | 9.0 |
| Surgery | 8.2 | 8.3 | 16.5 | 22.7 | NA |
| UC | | | | | |
| VEOIBD (< 6 yr) | 15.8 | NA | 7.1 | NA | NA |
| Age < 10 yr (A1a) | 42.0 | NA | 15.0 | 8.3 | - |
| Age 10-17 yr (A1b) | 58.0 | NA | 85.0 | 91.7 | - |
| Disease location in UC | | | | | |
| Proctitis | 3.2 | 2.4 | 12.4 | 20.8 | 5.0 |
| Upto splenic flexure | 25.8 | 24.4 | 15.0 | 12.5 | 18.0 |
| Upto hepatic flexure | NA | NA | 21.2 | 8.3 | 9.0 |
| Pancolitis | 70.9 | 73.1 | 51.3 | 58.4 | 69.0 |
| Surgery | 4.3 | 7.3 | 2.7 | NA | 9.0\(^*\) |

Value are presented as percent.

IBD, inflammatory bowel disease; PIBD, pediatric IBD; AIG, Asian Institute of Gastroenterology; EUROKIDS, European multicenter study of children with new-onset IBD; CD, Crohn's disease; UC, ulcerative colitis; IBD-U, IBD undifferentiated; VEOIBD, very early onset IBD; GI, gastrointestinal; NA, not available.
### Supplementary Table 4. Comparison of Adult and Pediatric Cohort in The Inflammatory Bowel Disease Registry

| Variable                        | PIBD cohort CD | Adult cohort CD<sup>22</sup> | PIBD cohort UC | Adult cohort UC<sup>22</sup> |
|--------------------------------|----------------|------------------------------|----------------|------------------------------|
| Male sex                        | 62.8           | 61.2                         | 63.7           | 61.4                         |
| Age at diagnosis (yr)           | 12.80 ± 3.89   | 34.00 ± 12.80                | 13.70 ± 3.91   | 38.20 ± 12.70                |
| Diagnostic delay (mo)           | 23.56 ± 27.76  | 42.2 ± 46.1                  | 19.37 ± 26.76  | 37.20 ± 43.80                |
| Smoking                         | 1.7            | 7.16                         | 0.8            | 7.63                         |
| History of ATT                  | 17.7           | 26.09                        | 1.7            | 1.21                         |
| Family history                  | 8.5            | 4.13                         | 9.7            | 4.34                         |
| Disease location in CD          |                |                              |                |                              |
| L1 (ileal)                      | 31.4           | 27.3                         |                |                              |
| L2 (colonic)                    | 37.1           | 24.3                         |                |                              |
| L3 (ileocolonic)                | 26.3           | 40.9                         |                |                              |
| Isolated L4 (Upper GI involvement) | 5.1           | 5.0                          |                |                              |
| B1 (Inflammatory)               | 57.1           | 67.8                         |                |                              |
| B2 (Stricturing)                | 31.4           | 22.9                         |                |                              |
| B3 (Fistulizing)                | 10.2           | 9.4                          |                |                              |
| Perianal disease                | 7.4            | 2.5                          |                |                              |
| Disease location in UC          |                |                              |                |                              |
| Proctitis                       |                |                              | 12.4           | 18.7                         |
| Proctosigmoiditis               |                |                              | 15.0           | 51.0                         |
| Beyond splenic flexure          |                |                              | 72.6           | 30.3                         |
| Treatment given (UC+CD)         |                |                              |                |                              |
| Steroids                        | 69.7           | 39.7                         | 56.6           | 39.5                         |
| Immunosuppressors               | 59.4           | 45.9                         | 38.9           | 34.6                         |
| Biologics                       | 5.7            | 5.7                          | 6.2            | 1.8                          |

Value are presented as percent or mean ± standard deviation.

IBD, inflammatory bowel disease; PIBD, pediatric IBD; CD, Crohn’s disease; UC, ulcerative colitis; ATT, anti-tubercular therapy; GI, gastrointestinal.